Michael Chen
Co-Founder/CEO
Nuclera
Nuclera's eProtein Discovery system utilizes cell-free protein synthesis and digital microfluidics to automate the screening, expression, and purification of proteins, delivering active protein samples in under 48 hours. This technology enables researchers to rapidly access and prototype target proteins, significantly accelerating drug discovery workflows.
- Biotechnology
- Hardware
Updated 23 months ago
Funding
Raised to date
$75MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Traditional protein expression and purification methods are time-consuming and labor-intensive, often requiring weeks or months to produce target proteins. This slow turnaround hinders early-stage drug discovery workflows, limiting the ability to rapidly screen and prototype protein variants.
Solution
Nuclera's eProtein Discovery system accelerates protein production by integrating cell-free protein synthesis with digital microfluidics. This automated platform enables researchers to screen, express, and purify proteins in under 48 hours, delivering active protein samples directly to their benchtop. The system supports simultaneous screening of multiple constructs and expression conditions, allowing for rapid optimization and identification of the best conditions for protein production. By streamlining the protein prototyping process, eProtein Discovery empowers scientists to test hypotheses more efficiently and de-risk target proteins earlier in the drug discovery pipeline.
Target Audience
The primary users are researchers in pharmaceutical and biotechnology companies involved in drug discovery, lead discovery, and protein engineering.
Features
- Automated protein expression and purification in under 48 hours
- Digital microfluidics for precise control of reaction conditions
- Simultaneous screening of up to 192 expression conditions
- Ability to explore up to 24 protein variations, including homologs, orthologs, mutations, and isoforms
- Intuitive software interface for easy workflow management
- Cell-free protein synthesis eliminates the need for cell culture
- Compact benchtop instrument design